Exabis Library
Welcome to the e-CCO Library!
P594: Vedolizumab dose intensification does not always improve treatment persistence.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREG
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P595: Early medical therapy and risk of subsequent perianal fistula development among paediatric patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P595: Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P595: The influence of vitamin D on expression of cytokines mRNA in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P595: Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P596: Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experience
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P596: An ongoing safety registry to identify rare and severe complications in children with paediatric-onset IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P596: Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P596: Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P596: Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P597: Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P597: Cycling Anti-TNF Therapy in Inflammatory Bowel Disease: Effectiveness and Durability of Switching from adalimumab to infliximab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P597: Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposure
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P597: Optimising therapeutic drug monitoring of adalimumab with dried blood samples in IBD patients: an interim analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM